BR112014019704A8 - Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo - Google Patents

Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo

Info

Publication number
BR112014019704A8
BR112014019704A8 BR112014019704A BR112014019704A BR112014019704A8 BR 112014019704 A8 BR112014019704 A8 BR 112014019704A8 BR 112014019704 A BR112014019704 A BR 112014019704A BR 112014019704 A BR112014019704 A BR 112014019704A BR 112014019704 A8 BR112014019704 A8 BR 112014019704A8
Authority
BR
Brazil
Prior art keywords
compounds
prevention
treatment
pharmaceutical composition
neurodegenerative disorder
Prior art date
Application number
BR112014019704A
Other languages
English (en)
Other versions
BR112014019704B1 (pt
BR112014019704A2 (pt
Inventor
S J Blagg Brian
Reddy Kusuma Bhaskar
Sundstrom Teather
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of BR112014019704A2 publication Critical patent/BR112014019704A2/pt
Publication of BR112014019704A8 publication Critical patent/BR112014019704A8/pt
Publication of BR112014019704B1 publication Critical patent/BR112014019704B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

COMPOSTOS INIBIDORES DE HSP90 C-TERMINAIS, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS DITOS COMPOSTOS E USO DOS MESMOS. A presente invenção fornece inibidores de Hsp90 C-terminais e composições farmacêuticas contendo tais compostos. Os compostos da invenção são úteis para o tratamento e/ou prevenção de distúrbios neurodegenerativos, tais como neuropatia periférica diabética.
BR112014019704-0A 2012-02-09 2013-02-08 Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo BR112014019704B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597004P 2012-02-09 2012-02-09
US61/597,004 2012-02-09
PCT/US2013/025387 WO2013119985A1 (en) 2012-02-09 2013-02-08 C-terminal hsp90 inhibitors

Publications (3)

Publication Number Publication Date
BR112014019704A2 BR112014019704A2 (pt) 2017-06-20
BR112014019704A8 true BR112014019704A8 (pt) 2017-07-11
BR112014019704B1 BR112014019704B1 (pt) 2022-05-31

Family

ID=47754998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019704-0A BR112014019704B1 (pt) 2012-02-09 2013-02-08 Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo

Country Status (24)

Country Link
US (6) US9422320B2 (pt)
EP (2) EP3656758B1 (pt)
JP (1) JP6121450B2 (pt)
KR (1) KR102124109B1 (pt)
CN (2) CN107474085B (pt)
AU (1) AU2013216858C1 (pt)
BR (1) BR112014019704B1 (pt)
CA (1) CA2866814C (pt)
CY (1) CY1122358T1 (pt)
DK (2) DK3656758T3 (pt)
EA (1) EA027147B1 (pt)
ES (1) ES2755093T3 (pt)
FI (1) FI3656758T3 (pt)
HK (2) HK1205131A1 (pt)
HR (1) HRP20191940T1 (pt)
HU (1) HUE046939T2 (pt)
LT (2) LT3656758T (pt)
MX (1) MX361233B (pt)
NZ (1) NZ629778A (pt)
PL (1) PL2812341T3 (pt)
PT (2) PT3656758T (pt)
RS (2) RS59719B1 (pt)
SI (1) SI2812341T1 (pt)
WO (1) WO2013119985A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3656758T (pt) 2012-02-09 2024-03-27 Univ Kansas Intermediários para a preparação de inibidores do cterminal de hsp90
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
SG11201610677XA (en) * 2014-06-24 2017-01-27 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2016145219A1 (en) * 2015-03-10 2016-09-15 University Of Florida Research Foundation, Inc. Treatment of peripheral neuropathies
CN112020506A (zh) 2018-02-07 2020-12-01 里亚塔医药公司 新生霉素类似物与脯氨酸的共晶体形式
IL278698B2 (en) * 2018-05-14 2024-06-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
MX2009009936A (es) 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) * 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
PT3656758T (pt) 2012-02-09 2024-03-27 Univ Kansas Intermediários para a preparação de inibidores do cterminal de hsp90
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
EP3068778A2 (en) 2013-11-11 2016-09-21 The University of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
SG11201610677XA (en) 2014-06-24 2017-01-27 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers

Also Published As

Publication number Publication date
CA2866814C (en) 2021-02-16
US10882881B2 (en) 2021-01-05
RS59719B1 (sr) 2020-01-31
HK1205131A1 (en) 2015-12-11
CA2866814A1 (en) 2013-08-15
BR112014019704B1 (pt) 2022-05-31
CY1122358T1 (el) 2021-01-27
EP3656758A1 (en) 2020-05-27
PL2812341T3 (pl) 2020-03-31
JP2015506982A (ja) 2015-03-05
US20190023730A1 (en) 2019-01-24
EA027147B1 (ru) 2017-06-30
HRP20191940T1 (hr) 2020-01-10
CN107474085A (zh) 2017-12-15
CN104271587B (zh) 2017-09-12
US9422320B2 (en) 2016-08-23
US10030041B2 (en) 2018-07-24
EA201491496A1 (ru) 2015-01-30
NZ629778A (en) 2016-03-31
SI2812341T1 (sl) 2020-02-28
US20200283465A1 (en) 2020-09-10
DK2812341T3 (da) 2019-11-18
JP6121450B2 (ja) 2017-04-26
KR102124109B1 (ko) 2020-06-17
US11390640B2 (en) 2022-07-19
US20170051000A1 (en) 2017-02-23
EP2812341A1 (en) 2014-12-17
MX2014009608A (es) 2015-05-20
AU2013216858B2 (en) 2017-08-24
CN107474085B (zh) 2021-05-11
LT2812341T (lt) 2019-12-10
PT2812341T (pt) 2019-11-22
US20230102047A1 (en) 2023-03-30
AU2013216858A1 (en) 2014-09-18
HUE046939T2 (hu) 2020-04-28
BR112014019704A2 (pt) 2017-06-20
US20210188891A1 (en) 2021-06-24
US20150057240A1 (en) 2015-02-26
HK1249519A1 (zh) 2018-11-02
US10590157B2 (en) 2020-03-17
DK3656758T3 (da) 2024-04-22
FI3656758T3 (fi) 2024-04-22
PT3656758T (pt) 2024-03-27
MX361233B (es) 2018-11-30
AU2013216858C1 (en) 2018-03-01
CN104271587A (zh) 2015-01-07
RS65412B1 (sr) 2024-05-31
KR20150001729A (ko) 2015-01-06
WO2013119985A1 (en) 2013-08-15
ES2755093T3 (es) 2020-04-21
EP2812341B1 (en) 2019-08-28
LT3656758T (lt) 2024-05-10
EP3656758B1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12017501306A1 (en) Inhibitors of histone demethylases
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112014030386A2 (pt) compostos e composições para modular a atividade de egfr
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
BR112017008714A2 (pt) inibidores de bromodomínio
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112012005957A2 (pt) compostos tricíclicos e usos farmacêuticos dos mesmos
BR112014022780A2 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
ECSP14004595A (es) 2-tiopirimidinonas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2013, OBSERVADAS AS CONDICOES LEGAIS